TAP Consulting’s AbbVie ABBV Stock Holding History

TAP Consulting’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,477	Closed	-$200K	–	136
2021 Q4	$200K	Buy	+1,477	New	+$174K	0.05%	135

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TAP Consulting's ABBV Position: Q1 2022 in Review

TAP Consulting sold out of AbbVie (ABBV) in Q1 2022, closing a stake of 1,477 shares — an estimated $200K sold.

TAP Consulting first reported a position in ABBV in Q4 2021 and held it in 1 quarter. The position peaked at $200K in Q4 2021. 3,053 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.

TAP Consulting reported no remaining AbbVie position as of Q1 2022 after selling out during the quarter.
TAP Consulting sold 1,477 AbbVie shares in Q1 2022, an estimated $200K.
TAP Consulting first reported a position in AbbVie in Q4 2021 and held it in 1 quarter.
TAP Consulting's AbbVie position peaked at $200K in Q4 2021.
3,053 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.

Based on TAP Consulting's 13F filing for Q1 2022, filed 26 Apr 2022.